Surmodics, Inc. Price & Performance (SRDX)

Federal regulators have filed a lawsuit to prevent GTCR's $627 million acquisition of Surmodics, raising concerns about reduced competition and higher healthcare costs. The FTC argues the deal would give GTCR control over a majority of the hydrophilic coatings market, impacting innovation and pricing for medical devices. Surmodics plans to contest the decision.12

Alpine Global Management acquired a $1.98 million position in Surmodics during Q4, while other major investors like State Street and Barclays also boosted their holdings. Institutional ownership now exceeds 96%, reflecting continued interest despite recent regulatory hurdles and fluctuating stock performance.34

The TRANSCEND trial results for Surmodics’ SurVeil drug-coated balloon have been published, demonstrating the product’s efficacy in treating peripheral artery disease. The study’s release is seen as a milestone for Surmodics’ innovation pipeline, potentially bolstering its competitive position in the vascular intervention market.567